Historique de carrière de Gert Adam Irma Thijs
Anciens postes connus de Gert Adam Irma Thijs
Sociétés | Poste | Début | Fin |
---|---|---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Fondateur | 28/08/2009 | 11/05/2012 |
Corporate Officer/Principal | 01/01/2005 | 11/05/2012 |
Formation de Gert Adam Irma Thijs
Université Catholique de Louvain | Undergraduate Degree |
Statistiques
Internationale
Belgique | 3 |
Opérationnelle
Founder | 1 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
- Bourse
- Insiders
- Gert Adam Irma Thijs
- Expérience